Copyright © BetaNXT, Inc. or its affiliates. All rights reserved.
September 8, 2026
2:00 p.m. PT
*Note: You must register to be eligible to participate in the meeting.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). AlloNK is currently being evaluated in three ongoing clinical trials, including a company-sponsored basket trial across autoimmune diseases, which includes rheumatoid arthritis and Sjögren’s disease, and an investigator-initiated basket trial in B-cell driven autoimmune diseases.
Copyright © BetaNXT, Inc. or its affiliates. All rights reserved.